Long-term functional outcomes improved with deep brain stimulation in patients with disorders of consciousness

Yi Yang,1,2,3 Qiheng He,1 Yuanyuan Dang,4 Xiaoyu Xia,4 Xin Xu,4 Xueling Chen,1 Jizong Zhao,1,5 Jiazhong He1

ABSTRACT

Background Deep brain stimulation (DBS) has been preliminarily applied to treat patients with disorders of consciousness (DoCs). The study aimed to determine whether DBS was effective for treating patients with DoC and identify factors related to patients' outcomes.

Methods Data from 365 patients with DoCs who were consecutively admitted from 15 July 2011 to 31 December 2021 were retrospectively analysed. Multivariate regression and subgroup analysis were performed to adjust for potential confounders. The primary outcome was improvement in consciousness at 1 year.

Results An overall improvement in consciousness at 1 year was achieved in 32.4% (12/37) of the DBS group compared with 4.3% (14/328) of the conservative group. After full adjustment, DBS significantly improved consciousness at 1 year (adjusted OR 11.90, 95% CI 3.65−38.46, p<0.001). There was a significant treatment×follow-up interaction (H=14.99, p<0.001). DBS had significantly better effects in patients with minimally conscious state (MCS) compared with patients with vegetative state/unresponsive wakefulness syndrome (p for interaction <0.001). A nomogram based on age, state of consciousness, pathogeny and duration of DoCs indicated excellent predictive performance (c-index=0.882).

Conclusions DBS was associated with better outcomes in patients with DoC, and the effect was likely to be significantly greater in patients with MCS. DBS should be cautiously evaluated by nomogram preoperatively, and randomised controlled trials are still needed.

INTRODUCTION

Disorders of consciousness (DoCs) are neuropsychiatric disturbances in arousal and awareness that are commonly caused by trauma, stroke or anoxia.1–3 DoCs encompass comas (unconscious), vegetative state/unresponsive wakefulness syndrome (VS/UWS; awake yet unresponsive) and minimally conscious state (MCS; inconsistent but clearly discernible behavioural evidence of self-awareness or environmental awareness).4 5 Such conditions present challenges for clinicians, as the overall possibility of spontaneous recovery is low.6 7 Efforts have been made to identify whether neuromodulation therapy facilitates recovery; however, evidence is limited.4 8 9

Deep brain stimulation (DBS), as a potential promising neuromodulatory technique, involves implanting electrodes that can electrically stimulate specific structures of deep brain regions and modify abnormal neural pathways; this treatment has been widely applied for patients with Parkinson's disease, epilepsy and other psychiatric diseases.10–12 In 2007, Schif et al reported treating a patient with traumatic brain injury with DBS of the central thalamic nuclei and observed behavioural improvements.13 Since then, only seven studies of DBS including 46 patients with DoC have been published, and the results are inconsistent due to small sample sizes and missing control groups.14–19 Thus, the existing data are limited, and the factors that may influence the long-term effects of DBS remain unclear. In this study, we consecutively enrolled patients with DoCs

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Disorders of consciousness (DoCs) impose heavy medical and economic burdens on families and society. Deep brain stimulation (DBS) may be an effective treatment for these patients.

WHAT THIS STUDY ADDS

⇒ DBS significantly improved patient consciousness at 1 year, and enhanced therapeutic effects were found in patients with minimally conscious state. We constructed a nomogram based on age, state of consciousness, and pathogeny and duration of DoCs; this nomogram showed excellent predictive performance as a clinical tool.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ DBS is likely to be effective for treating DoCs and should be cautiously evaluated by nomogram preoperatively.
who received DBS or conservative treatment in our
department and summarised the results of follow-ups.
Additionally, we analysed the factors related to the long-
term effects of DBS in patients with DoC and discussed
the potential basis for preoperative screening to provide
evidence for precision treatment options for patients
with DoCs.

MATERIALS AND METHODS
Study participants
We recruited 421 consecutive patients who were admitted
to the Departments of Disorders of Consciousness at the
People’s Liberation Army General Hospital and Beijing
Tiantan Hospital, Capital Medical University, from 15 July
2011 to 31 December 2021. The inclusion criteria were
as follows: patients who (1) were diagnosed with a DoC
according to their score on the JFK Coma Recovery Scale-
Revised (CRS-R)20; (2) had a duration of DoC >3 months;
and (3) family or surrogates provided written informed
consent. The exclusion criteria were as follows: patients
with (1) sudden DoCs caused by gradual deterioration of
neurological function or (2) progressive improvement
or deterioration of consciousness for more than four
consecutive weeks. After application of the inclusion and
exclusion criteria, 365 patients who underwent follow-up
were included. The patient recruitment flow chart is
shown in online supplemental figure S1. The treatment
options, possible risks of treatment and the nature of DBS
for DoCs were explained to each patient’s legal representa-
tive and/or close relatives, as these patients were unable
to understand or legally provide their consent. The
caregivers were offered an informed consent form that
followed the internationally adopted ethical standards for
the performance of clinical treatment and research (the
Declaration of Helsinki). Once their caregivers provided
written informed consent, the patients were enrolled in
the study.

Data collection and outcomes
Data on demographic characteristics, clinical features
and radiological examinations were extracted from the
electronic medical record system. Demographic charac-
teristics included age, sex, pathogeny and duration of
DoCs at admission. Clinical features included state of
consciousness. Radiological examinations include MRI,
electroencephalography (EEG), the mismatch negativity
(MMN) and CT. Outpatient follow-up was performed
6 months and 1 year after discharge, and patients’
Glasgow Outcome Scale (GOS) score, CRS-R score and
radiological examinations were recorded. Improvement
in consciousness was defined improvement of more than
3 points on the CRS-R; the primary outcome of the study
was improvement in consciousness at 1 year. Secondary
outcomes included improvement in consciousness at 6
months and emergence from unconsciousness, defined
as a GOS score >2 at 6 months and 1 year.

JFK CRS-R scores and follow-up
The CRS-R was used to assess the level of consciousness
of each patient. Scores on this scale may vary from 0 to
23, and six subscores are used to quantify auditory, visual,
motor and verbal functions as well as communication
and arousal. CRS-R scores at admission were obtained
through repeated assessments (minimum of five assess-
ments within 2 weeks) prior to DBS to avoid fluctuations
of consciousness. The scale was applied by trained profes-
sionals, who recorded the highest of the scores as the
consciousness level at admission. CRS-R scores were
regularly determined at each follow-up, after surgery and
before discharge (once a week). During the COVID-19
pandemic, we scored patients through video calls to
collect follow-up data. We did the video assessment with
video software (PINS, China) under the supervision of a
certificated doctor. Patient port: JOINPINS (PINS) soft-
ware+patient program controller C702 (also 701 or 802);
docor port: remote program system (PINS). Patients
with DoC are mostly in rehabilitation centres with bedside
doctors.

Neuroradiological and electrophysiological evaluation
MRI and resting-state functional MRI (fMRI) were
performed using a 3.0 T MRI scanner (HD750, GE,
USA) to evaluate brain atrophy and damage to critical
brain regions and to calculate brain network activation
and connectivity (https://github.com/realmsong504/
pDOC). Preoperative EEG data were collected from
all patients for at least 2 hours using an EEG recording
device (BrainAmp 64 MRplus, Brain Products, Germany);
subsequently, a trained senior clinician scored the EEG
data according to the Synenk grading scale.

Surgical indications
The general indications for DBS surgery were as follows:
(1) no large-area skull defects, no skull repair or shunt
pump placement; (2) no major complications or contrain-
dications to surgery; and (3) structurally intact bilateral
thalamus. We also explored whether patients who were
highly recommended for DBS according to the criteria
had a better outcome than patients who were weakly
recommended after receiving DBS. Notably, these criteria
were not used to select among treatment options in these
patients. Therefore, patients who received DBS under-
went preoperative MRI, EEG and MMN wave examina-
tion as previously reported.21–23 Briefly, patients who met
more than two of the following criteria were considered
highly recommended: (1) focal brain damage <30%, (2)
probability of emergence from unconsciousness >30%
according to the prolonged DoC analysis tool,25 (3) MMN
wave >1.26 and (4) Synenk grade <3.27

DBS surgical approach and stimulation protocol
Regarding development of the preoperative plan, the
surgical path was designed to avoid the lateral ventricles.
Patients were mounted with a stereotactic instrument
base ring under general anaesthesia. Axial, coronal and
sagittal T1-weighted MRI sequences were performed after the installation of the Leksell G head frame (Elekta, Sweden), with a scan thickness of 2 mm. The electronic atlas of thalamic nuclei in the assisted surgical planning system is superimposed to improve the accuracy of intraoperative positioning.

Further, all the T1-weighted MR images were processed using the CIVET pipeline (https://www.bic.mni.mcgill.ca/ServicesSoftware/CIVET), developed at the Montreal Neurological Institute (MNI) for morphometric analyses of human MR images. First, the images were corrected for non-uniformity artefacts using the N3 algorithms. The individual structural MR images were then transformed into the standardised MNI space using linear and non-linear transformations by registering to a standard brain imaging template (International Consortium for Brain Mapping 152). Second, the CM/Pf nuclei extracted from Morel’s histological thalamus atlas in the MNI space were selected as region of interest (ROI) and registered to native T1 space by reversing the transformation parameters.

As for the imaging features of the enrolled patients, the length of the anterior commissure-posterior commissure (AC-PC) line was (24.6 ± 3.2) mm. The anatomical coordinates of centre median-parafascicular (CM-Pf) were: 7.8–9.7 mm behind the midpoint of the AC-PC line, 8.8–10.5 mm from the AC-PC line (4.5–5.5 mm from the ventricular wall) and 0–1.5 mm downward from the AC-PC plane. An electrode (3387, Medtronic, USA) was implanted into the CM-Pf complex. During the operation, the microelectrodes recorded that the discharge activity of the single cells in the CM-Pf was significantly lower than that of the surrounding nuclei, almost in a silent state, which can assist in judging the location of the target. When making a preoperative surgical plan, avoid the lateral ventricle when planning the path. The implantable pulse generator (IPG, G102RZ) was placed at the midpoint of an imaginary line between the subclavian and anterior axillary lines and the middle sternal line. Postoperative CT or MRI scans were performed to confirm the implantation location.

The IPGs were activated 7 days after surgery, when the wound healed and the local oedema caused by the puncture subsided. Periodic electrical stimulation was administered to the brains of patients. The main source of stimulation was monopolar with a frequency of 100 Hz, 120 μs and 1.0–4.0 V. Stimulation was provided continuously from 08:00 to 20:00 hours with a 15 min on/off cycle (15 mins on, 15 mins off). The Kolmogorov-Smirnov test. After follow-up; 37 of these patients (10.1%) received DBS. Patients with DoCs were further categorised according to their state of consciousness: 123 out of 365 (33.7%) patients were in an MCS and 242 out of 365 patients (66.3%) were in a VS/UWS (online supplemental table S1). In this cohort, 253 (69.3%) patients were male, and the median age was 49.0 (35.0–58.0) years. No significant differences in terms of age (Wilcoxon rank-sum test, p=0.431) or sex (χ² test, p=0.349) were observed between the DBS and conservative treatment groups.

Regarding pathogenicity, there were 136 trauma cases (37.3%), 164 stroke cases (44.9%) and 65 anoxia cases (17.8%); no significant difference was found in terms of state of consciousness of these patients (χ² test, p=0.080). Regarding the duration of DoCs, the DBS group had significantly more patients with shorter durations (25, 67.6%) than the conservative treatment group (40, 12.2%) (χ² test, p<0.001). Regarding the prevalence of MCS, there were 13 (35.1%) patients with MCS in the DBS group and 110 (33.5%) patients with MCS in the conservative treatment group; this difference was not significant (χ² test, p=0.856).

Data from the 37 patients who received DBS were further analysed according to demographic characteristics and state of consciousness (online supplemental table S2). The median age in the DBS group was 35.0 (26.0–48.5) years among patients with MCS and 49.5 (41.0–59.8) years among patients with VS/UWS; thus, the ages significantly differed (χ² test, p=0.002). The sex distribution was not significantly different between the MCS and VS/UWS subgroups (χ² test, p=0.288). In the VS/UWS subgroup, significantly more patients had DoC caused by stroke (15, 62.5%) compared with that caused by trauma (2, 8.3%) (χ² test, p=0.025). The VS/UWS subgroup also contained more patients with a 3–5 months’ duration of DoC (21, 87.5%) than the MCS subgroup (4, 30.8%, χ² test, p=0.002). Regarding the recommendation criteria, both subgroups contained eight patients who were highly recommended for DBS; no significant group difference was found (χ² test, p=0.098).

### Statistical analysis

SPSS V.25 (IBM), Prism V.8 (GraphPad Software, USA) and R V.4.2.1 (USA) were used for statistical analyses. The normality of data distribution was evaluated using the Kolmogorov-Smirnov test. For continuous variables, normally distributed data are presented as the mean±SD and compared using a t-test; non-normally distributed data are presented as the median (IQR) and compared using the Wilcoxon rank-sum test. The χ² test was used to compare categorical data. Repeated measures data that were not normally distributed were analysed using the Scheirer-Ray-Hare test. A two-tailed p value <0.05 was considered to indicate statistical significance.

### RESULTS

#### Study population

We included 365 patients with DoCs who met the inclusion criteria and underwent follow-up; 37 of these patients (10.1%) received DBS. Patients with DoCs were further categorised according to their state of consciousness: 123 out of 365 (33.7%) patients were in an MCS and 242 out of 365 patients (66.3%) were in a VS/UWS (online supplemental table S1). In this cohort, 253 (69.3%) patients were male, and the median age was 49.0 (35.0–58.0) years. No significant differences in terms of age (Wilcoxon rank-sum test, p=0.431) or sex (χ² test, p=0.349) were observed between the DBS and conservative treatment groups. Regarding pathogenicity, there were 136 trauma cases (37.3%), 164 stroke cases (44.9%) and 65 anoxia cases (17.8%); no significant difference was found in terms of state of consciousness of these patients (χ² test, p=0.080). Regarding the duration of DoCs, the DBS group had significantly more patients with shorter durations (25, 67.6%) than the conservative treatment group (40, 12.2%) (χ² test, p<0.001). Regarding the prevalence of MCS, there were 13 (35.1%) patients with MCS in the DBS group and 110 (33.5%) patients with MCS in the conservative treatment group; this difference was not significant (χ² test, p=0.856).

Data from the 37 patients who received DBS were further analysed according to demographic characteristics and state of consciousness (online supplemental table S2). The median age in the DBS group was 35.0 (26.0–48.5) years among patients with MCS and 49.5 (41.0–59.8) years among patients with VS/UWS; thus, the ages significantly differed (χ² test, p=0.002). The sex distribution was not significantly different between the MCS and VS/UWS subgroups (χ² test, p=0.288). In the VS/UWS subgroup, significantly more patients had DoC caused by stroke (15, 62.5%) compared with that caused by trauma (2, 8.3%) (χ² test, p=0.025). The VS/UWS subgroup also contained more patients with a 3–5 months’ duration of DoC (21, 87.5%) than the MCS subgroup (4, 30.8%, χ² test, p=0.002). Regarding the recommendation criteria, both subgroups contained eight patients who were highly recommended for DBS; no significant group difference was found (χ² test, p=0.098).

#### Clinical characteristics of patients with DoC according to their outcome

To determine whether DBS was an effective treatment for patients with DoC, we first aimed to determine the proportion of patients who exhibited improvements in consciousness according to changes in their CRS-R scores. After follow-up for 1 year, 26 of the 365 overall patients (7.1%), regardless
of whether they received DBS or conservative treatment, exhibited improvements in consciousness (table 1). While the median age in the improved group was slightly younger (36.5 (26.0–55.5)) than that in the unchanged group (49.0 (36.0–58.0)), this difference was not significant (Wilcoxon rank-sum test, p=0.078), nor were there significant differences in the sex distribution (χ² test, p=0.992). The improved and unchanged groups did not differ in pathogeny (χ² test, p=0.375). Regarding state of consciousness, significantly more patients were initially diagnosed with MCS in the improved group (18, 69.2%) than in the unchanged group (105, 31.0%, χ² test, p<0.001). We also found more patients with durations of DoC greater than 12 months in the unchanged group (233, 68.7%) than in the improved group (10, 38.5%, χ² test, p=0.006). In general, DBS appears to improve patient outcomes: significantly more patients improved at 1 year if they received DBS (32.4% (12/37) vs 4.3% (14/328), χ² test, p<0.001), and when emergence from unconsciousness was assessed by GOS scores, consistently more patients emerged from unconsciousness if they received DBS (χ² test, p<0.001). Notably, we did not find a significant difference in the duration of DoCs between the improved and unchanged groups, in contrast to findings in the whole sample (χ² test, p=0.286).

Furthermore, we examined the effect of the interaction between state of consciousness (MCS vs VS/UWS) and follow-up period (6 months vs 1 year) on improvement in patients who received DBS (figure 1). We observed a statistically significant difference in the improvement in consciousness between patients with MCS and VS/UWS who underwent DBS (Scheirer-Ray-Hare test, H=5.86, p=0.016). The treatment (DBS vs conservative) × follow-up period interaction had a significant effect on the improvement in consciousness (Scheirer-Ray-Hare test, H=6.31, p=0.043). We also found a significant effect of the treatment×follow-up interaction on the outcome differences (Scheirer-Ray-Hare test, treatment, H=18.56, p<0.001; follow-up, H=20.56, p<0.001; treatment×follow-up interaction, H=14.99, p<0.001).

Table 1 Clinical characteristics of patients with DoC according to their outcome

<table>
<thead>
<tr>
<th>Variable</th>
<th>Outcome</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Improved (n=26)</td>
<td>Unchanged/died (n=339)</td>
</tr>
<tr>
<td>Age, years, median (IQR)</td>
<td>36.5 (26.0–55.5)</td>
<td>49.0 (36.0–58.0)</td>
</tr>
<tr>
<td>Sex (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>18 (69.2)</td>
<td>235 (69.3)</td>
</tr>
<tr>
<td>Female</td>
<td>8 (30.8)</td>
<td>104 (30.7)</td>
</tr>
<tr>
<td>State of consciousness (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCS</td>
<td>18 (69.2)</td>
<td>105 (31.0)</td>
</tr>
<tr>
<td>VS/UWS</td>
<td>8 (30.8)</td>
<td>234 (69.0)</td>
</tr>
<tr>
<td>Pathogeny (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anoxia</td>
<td>2 (7.7)</td>
<td>63 (18.6)</td>
</tr>
<tr>
<td>Stroke</td>
<td>13 (50.0)</td>
<td>151 (44.5)</td>
</tr>
<tr>
<td>Trauma</td>
<td>11 (42.3)</td>
<td>125 (36.9)</td>
</tr>
<tr>
<td>Duration at admission (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3–5 months</td>
<td>8 (30.8)</td>
<td>57 (16.8)</td>
</tr>
<tr>
<td>6–11 months</td>
<td>8 (30.8)</td>
<td>49 (14.5)</td>
</tr>
<tr>
<td>≥12 months</td>
<td>10 (38.5)</td>
<td>233 (68.7)</td>
</tr>
<tr>
<td>Treatment (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBS</td>
<td>12 (46.2)</td>
<td>25 (7.4)</td>
</tr>
<tr>
<td>Conservative</td>
<td>14 (53.8)</td>
<td>314 (92.6)</td>
</tr>
</tbody>
</table>

*P<0.05, significant difference.

DBS, deep brain stimulation; DoC, disorder of consciousness; MCS, minimally conscious state; VS/UWS, vegetative state/unresponsive wakefulness syndrome.
Analysis of primary and secondary outcomes

Regarding the primary outcome, after adjusting for age, sex, state of consciousness, pathogeny and duration of DoC, DBS was significantly associated with the improvement in consciousness at 1 year (DBS: 12/37 (32.4%) vs conservative treatment: 14/328 (4.3%); logistic analysis, absolute difference: 10.75 (4.50 to 25.64); adjusted OR (aOR): 11.90 (3.65–38.46), p<0.001; table 2).

Regarding the secondary outcomes, after full adjustment in the multivariate regression, the significant association of DBS and improvement in consciousness at 6 months persisted (DBS: 5/37 (13.5%) vs conservative treatment: 10/328 (3.0%); logistic analysis, absolute difference: 4.98 (1.60 to 15.38); aOR: 4.48 (1.11–18.18), p=0.036; table 2). DBS was significantly associated with better GOS scores at 1 year (χ² test, p<0.001) as well as emergence from unconsciousness at 1 year (DBS: 14/37 (37.8%) vs conservative treatment: 44/328 (13.4%); logistic analysis, absolute difference: 3.92 (1.88 to 8.20); aOR: 6.62 (2.28–19.23), p=0.001). The results suggest DBS is associated with better outcomes in patients with DoC.

Subgroup analysis within patients who received DBS

After establishing that DBS led to improved overall patients’ outcomes, we next investigated in whom would particularly benefit from DBS. Subgroup analysis was performed with the outcome of the improvement of consciousness at 1 year (figure 2). The therapeutic effects of DBS among subgroups of patients did not significantly vary according to age (p for interaction=0.078), sex (p for interaction=0.299), pathogeny (p for interaction=0.070) or duration of DoCs (p for interaction=0.880). The therapeutic effects of DBS significantly differed according to state of consciousness (MCS: aOR=55.56 (10.31–333.33); VS/UWS: aOR=6.76 (0.97–47.62); p value for interaction: 0.033). Consistent with this finding, the GOS scores (χ² test, p<0.001) and likelihood of emergence from unconsciousness at 1 year were significantly higher in MCS (χ² test, p=0.001), and the GOS scores were significantly higher in MCS (χ² test, p<0.001).

Table 2

<table>
<thead>
<tr>
<th>Outcome</th>
<th>DBS group (n=37)</th>
<th>Conservative group (n=328)</th>
<th>Absolute difference (95% CI)</th>
<th>Adjusted OR* (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improvement in consciousness</td>
<td>12/37 (32.4)</td>
<td>14/328 (4.3)</td>
<td>10.75 (4.50–25.64)</td>
<td>11.90 (3.65–38.46)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Secondary outcomes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Improvement in consciousness at 6 months</td>
<td>5/37 (13.5)</td>
<td>10/328 (3.0)</td>
<td>4.98 (1.60–15.38)</td>
<td>4.48 (1.11–18.18)</td>
<td>0.036</td>
</tr>
<tr>
<td>GOS score at 1 year, n/total (%)</td>
<td>1/37 (0.0)</td>
<td>0/328 (0.0)</td>
<td></td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>22/37 (59.5)</td>
<td>284/328 (86.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>8/37 (21.6)</td>
<td>39/328 (11.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>3/37 (8.1)</td>
<td>5/328 (1.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>3/37 (8.1)</td>
<td>0 (0.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emergence from unconsciousness at 1 year, n/total (%)</td>
<td>14/37 (37.8)</td>
<td>44/328 (13.4)</td>
<td>3.92 (1.88–8.20)</td>
<td>6.62 (2.28–19.23)</td>
</tr>
</tbody>
</table>

*Adjusted for patient age, sex, diagnosis, pathogeny and duration of disorders of consciousness (DoCs).

P values <0.05 indicate significant differences.
unconsciousness ($\chi^2$ test, $p<0.001$) were significantly better in patients with MCS than in patients with VS/UWS in the DBS group (online supplemental table S4).

**Analysis of related factors and nomogram of the therapeutic effects of DBS**

We further analysed the potential factors associated with therapeutic effects of DBS in patients with DoCs; the results are shown in table 3. After adjusting for all covariates, state of consciousness was the only factor that was significantly associated with the therapeutic effect of DBS (MCS: 10/12 (83.3%) vs VS/UWS: 2/24 (8.3%); logistic analysis, aOR: 68.400 (1.460–3203.834), $p=0.031$).

We also constructed a nomogram based on potential related factors, including age, state of consciousness, and pathogeny and duration of DoC. The nomogram achieved a $c$-index of 0.882, which is shown in figure 3. We also generated calibration curves for the nomogram, which are shown in online supplemental figure S2. The mean absolute error of the nomogram was 0.079. Then, we performed the Hosmer-Lemeshow goodness-of-fit test, which suggested that the model was well calibrated ($\chi^2=5.435$, $p=0.710$). The results suggest that the nomogram has an excellent predictive performance.

**Effect of DBS on CRS-R subscale scores**

In general, DBS significantly improved scores on the six subscales, namely audio ($p=0.009$), visual ($p=0.004$), motor ($p<0.001$) and verbal functions ($p<0.001$), as well as communication ($p<0.001$) and arousal ($p<0.001$) (Wilcoxon rank-sum test, figure 4A). In patients with MCS, similar results were found (table 4); significant improvements were observed in the audio ($p<0.001$), visual ($p=0.005$) and motor functions ($p<0.001$), as well as communication ($p<0.001$) and arousal ($p<0.001$); there was a small but significant difference in verbal function scores ($p=0.001$) (Wilcoxon rank-sum test, figure 4B). However, in patients with VS/UWS who received DBS, only the subscales of communication (p=0.006) and arousal (p=0.005) showed significant score improvement (Wilcoxon rank-sum test).

**DISCUSSION**

In this study, we found an overall improvement in consciousness at 1 year was achieved in 32.4% (12/37) of the DBS group compared with 4.3% (14/328) of the conservative group. DBS had significantly better effects

---

**Table 3** Logistic analysis of factors related to improvement in consciousness after DBS

<table>
<thead>
<tr>
<th>Variable</th>
<th>Multivariate analysis</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.893 (0.743–1.072)</td>
<td>0.224</td>
</tr>
<tr>
<td>Sex, female</td>
<td>0.232 (0.006–8.393)</td>
<td>0.425</td>
</tr>
<tr>
<td>State of consciousness, MCS</td>
<td>68.400 (1.460–3203.834)</td>
<td>0.031</td>
</tr>
<tr>
<td>Pathogeny</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Anoxia</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Stroke</td>
<td>16.988 (0.171–1683.366)</td>
<td>0.227</td>
</tr>
<tr>
<td>Trauma</td>
<td>29.939 (0.209–4287.686)</td>
<td>0.180</td>
</tr>
<tr>
<td>Duration of DoCs at admission</td>
<td>0.512 (0.041–6.313)</td>
<td>0.601</td>
</tr>
<tr>
<td>Recommendation criteria, highly recommended</td>
<td>0.104 (0.005–2.006)</td>
<td>0.134</td>
</tr>
</tbody>
</table>

*P<0.05, significantly different. DBS, deep brain stimulation; DoCs, disorders of consciousness; MCS, minimally conscious state.
in patients with MCS compared with patients with VS/UWS (p for interaction <0.001). We proposed the first nomogram to predict the therapeutic effects of DBS, and found that DBS was significantly associated with better long-term patient outcome and may represent a viable treatment option for patients with DoC, especially patients with MCS, as all six CRS-R subscales exhibited improvement after receiving DBS. To our knowledge, this study represents a novel comprehensive analysis of DBS in patients with DoCs.

DoCs are states of altered arousal, ranging from coma to unconsciousness, that occur after brain injury. Patients with DoCs have received a wide array of pharmacological and non-pharmacological treatments. To date, only amantadine administration has demonstrated benefits in a randomised placebo-controlled trial; this medication

![Figure 3](image_url) Nomogram of long-term outcome in patients with disorders of consciousness (DoCs) receiving deep brain stimulation (DBS). The pathogeny was classified as trauma or non-trauma (including stroke and anoxia). The therapeutic effect indicates the possibility of improvement in consciousness after receiving DBS in patients with DoCs; this probability ranged from 0 (unchanged/died) to 1 (effective). MCS, minimally conscious state; VS/UWS, vegetative state/unresponsive wakefulness syndrome.

![Figure 4](image_url) Radar chart for improvement in Coma Recovery Scale-Revised (CRS-R) subscores. (A) Deep brain stimulation (DBS) group and conservative group in overall patients. The blue line represents the DBS treatment group and the orange line represents the conservative treatment group. (B) Patients with minimally conscious state (MCS) and vegetative state/unresponsive wakefulness syndrome (VS/UWS) underwent DBS treatment. The blue line represents the MCS group and the orange line represents the VS/UWS group.
is recommended in the 2018 DoC guidelines. Since the late 1960s, patients with severe brain injury have been sporadically treated with DBS. However, as the concept of MCS had not yet been defined, some of the cases may have been misdiagnosed. In 2007, Schiff et al reported one patient with MCS who presented with coma for 6 years after brain injury; this patient was successfully awakened after DBS of the central thalamic nuclei. In their study, a parameter of 100 Hz, 4.0 V was used for stimulation, which is consistent with our study. Meanwhile, Dang et al studied nine patients with MCS who received 100 Hz DBS treatment, and proved 100 Hz DBS improved EEG functional connectivity and brain networks, indicating that the long-term use of DBS could improve the level of consciousness of patients with MCS. Therefore, we used 100 Hz for stimulation. Aspects of consciousness are based on two main components: wakefulness and awareness. Wakefulness refers to the patient’s level of arousal and is assessed by observing eye opening. Arousal is related to subjective experiences and can be subdivided into awareness of the external world (ie, perception of the environment or ‘consciousness’) and ‘awareness’ of the internal world (ie, stimulus-independent thoughts such as mental imagery and inner speech or ‘self-awareness’). Behavioural changes refer to the behavioural manifestations of the external environment and self-response. In 2020, Neuron published a study in which the anaesthetised macaques were stimulated, and a specific frequency (50 Hz) effectively restored wakefulness and wakefulness-like nerve process. In 2022, Tasserie et al used anaesthesia to suppress the consciousness of non-human primates. During anaesthesia, central thalamus stimulation induced increasing fMRI activity in the prefrontal, parietal and cingulate cortices. DBS restores two dimensions of consciousness, arousal and access to conscious content. Lemaire et al found that DBS improved visual and auditory processes and led to an increase in medial cortex activity. Magrassi et al found that DBS promoted desynchronisation of the power spectrum of EEGs and increased CRS-R scores. However, there is still a paucity of literature on the use of DBS in patients with DoC. Due to the ethical challenges of carrying out large, controlled studies in patients with DoC, the identified studies have been mostly limited to single-subject data and lack a sham control group. Thus, more research to evaluate the effectiveness of DBS for patients with DoC is urgently needed. In the present study, we included patients who underwent conservative treatment to compare its effects with that of DBS; we suggest that DBS may facilitate the recovery of patients with DoCs in a continuous manner. Notably, we found that patients with MCS had significantly better outcomes than patients with VS/UWS. Patients with MCS can follow certain commands; therefore, global connectivity and vital circuits are preserved in these patients, providing a basis for subsequent functional recovery through the application of DBS. This may explain the superior outcome in patients with MCS, and patients in VS/UWS should be more rigorously evaluated either clinically or in future researches.

Regarding the underlying mechanisms of the effect of DBS, the relevance of the mesencephalic reticular formation to alertness was confirmed in earlier studies that stimulation of the mesencephalic reticular formation induced arousal-like desynchronisation of the EEG. Moreover, a ‘mesocircuit’ model of forebrain dysfunction has been proposed as a potential mechanism underlying DoCs. Neurons within the central thalamic nuclei regulate arousal in the forebrain and may play an important role in forebrain dysfunction after brain injury. Damage to the central thalamic nuclei often results in severe and persistent loss of consciousness. Thus, DBS targeting the central thalamic nuclei may compensate for a loss of arousal regulation normally controlled by the frontal lobe in the intact brain, and the excitatory output generated by DBS targeting the central thalamic nuclei may normalise cortico-striatal-thalamo-cortical function in patients with DoCs whose background synaptic activity is chronically downregulated following brain injury. In the present study, the CM-Pf complex was selected as the DBS target in all 37 patients with DoC. As the central thalamic nuclei are approximately 7 mm in diameter and centrally located in the thalamus, three-dimensional brain map matching was used to select targets and guarantee the accuracy of electrode implantation, especially

<table>
<thead>
<tr>
<th>Variable</th>
<th>All (n=123)</th>
<th>DBS group (n=13)</th>
<th>Conservative group (n=110)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRS-R subscale</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Audio</td>
<td>0 (0–1)</td>
<td>2 (0–2.5)</td>
<td>0 (–1 to 1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Visual</td>
<td>0 (0–1)</td>
<td>2 (0–2)</td>
<td>0 (0–1)</td>
<td>0.005</td>
</tr>
<tr>
<td>Motor</td>
<td>0 (–1 to 1)</td>
<td>2 (1–3.5)</td>
<td>0 (–1 to 1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Verbal</td>
<td>0 (0–0)</td>
<td>0 (0–1)</td>
<td>0 (0–0)</td>
<td>0.001</td>
</tr>
<tr>
<td>Communication</td>
<td>0 (0–0)</td>
<td>1 (0–1.5)</td>
<td>0 (0–0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Arousal</td>
<td>0 (0–0)</td>
<td>1 (0–1)</td>
<td>0 (0–0)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

P<0.05, significantly different.

CRS-R, Coma Recovery Scale-Revised; DBS, deep brain stimulation; MCS, minimally conscious state.
for patients with DoC with large changes in brain structure. The CM-Pf complex constitutes a major portion of the intralaminar thalamus and provides strong connections to several subcortical structures. Previous studies have reported that the CM-Pf complex is a key structure in motor, associative-limbic and integrative circuits at the crossroads of the basal ganglia; Schiff captured its role by proposing the key participation of the central thalamic nuclei in arousal. Thus, the CM-Pf complex lies at the intersection of motor function and arousal, making it an ideal target for brain stimulation. The proper selection and precise targeting of targets are key to the success of DBS. The anatomical coordinates of targets can be clarified by preoperative imaging, and the neural electrophysiological signals can be recorded intraoperatively by microelectrodes to clarify the target cells, ensuring surgical precision. DBS in treating DoCs differs from tremor control, which requires continuous stimulation to suppress abnormal movements. In terms of DoC treatment, DBS mainly plays a role in maintaining nerve excitability, and does not require continuous stimulation. On the contrary, continuous stimulation will lead to fatigue and decreased nerve excitability of patients, so we adopted the strategy of intermittent stimulation. According to our previous experience that based on several spinal cord stimulation clinical studies, we believe that 15 min on and 15 min off is a very effective strategy.

We also compared the CRS-R and GOS before and after the patients received DBS, and found that the behaviour and consciousness level of the patients have improved significantly. CRS-R is more detailed in the behavioural improvement among patients with DoC, while GOS is a more feasible score to assess whether the patient emerged from unconsciousness, and the effect of DBS in patients with DoC is consistent. This inconsistency in subscale improvements highlights the need for more imaging studies to investigate the effects of DBS in patients with DoC and further clarify the underlying neural mechanism rather than allowing regional injury to guide future clinical directions.

In light of these mechanistic and clinical findings, factors related to the outcomes of DBS can be discussed. Nomogram is based on multifactor regression analysis, integrates multiple predictive indicators and then uses scaled line segments to draw on the same plane according to a certain ratio, so as to express the relationship between variables in the predictive model. The nomogram transforms the complex regression equation into a visual graph, making the results of the prediction model more readable and convenient for patient evaluation. It is precisely because of the intuitive and easy-to-understand characteristics of the nomogram that it has gradually received more and more attention and application in medical research and clinical practice. Although data are scarce, it is generally believed that patients with MCS have less damage to neurocircuitry than patients with VS/UWS, as their fMRI scans show more activated areas and increased connectivity, and patients with MCS have a better outcome. Of the 37 patients who received DBS in this study, 12 exhibited significant improvement after DBS, including two patients with VS/UWS and 10 patients with MCS. We explored whether the recommendation criteria used in spinal cord stimulation of patients with DoC would also be feasible for DBS criteria; however, no significant difference was found regarding highly or weakly recommended patients for DBS. This lack of difference may be because these two neuromodulation techniques (spinal cord stimulation vs DBS) have different neural mechanisms; the specific differences merit further study in DoC patients.

The recovery of patients with DoC involves multiple mechanisms that alter global neuronal function as well as specific neural circuits. According to our long-term follow-up, the therapeutic effect gradually decreased with increasing age, indicating that the high neuroplasticity and metabolic activity observed in childhood might decrease with age. Patients with DoC induced by trauma had significantly better outcomes than patients with DoC induced by other causes, which may be a result of local deficits rather than the diffuse brain injuries commonly observed in response anoxia that affect the connectivity of the whole brain. Additionally, we found that a longer duration of DoC was associated with worse outcomes of DBS, suggesting that timely stimulation may help rescue the remaining circuits. Moreover, we constructed a nomogram that allows intuitive assessment of the impact of these factors on the therapeutic effect. The Hosmer-Lemeshow goodness-of-fit test revealed that the model was well calibrated, and the c-index indicated that these factors were excellent at predicting therapeutic effects. Use of a preoperative screening tool is crucial because patients with DoC and their families face clinical dilemmas regarding treatment decisions. In the future, adding more electrophysiological and imaging indicators to the model facilitates identification of patients suitable for DBS.

**Limitations**

This study is retrospective, and due to limitations in the study design, it is difficult to fully exclude confounding factors that may influence the therapeutic effect after DBS. Overall, continuous significant improvement was observed at different time points in patients who received DBS, suggesting that the results are reliable. At the time of inclusion, we only included patients with a disease course of more than 3 months and no progressive increase in consciousness for two consecutive weeks or more, so the possibility of spontaneous recovery was strictly excluded. In addition, we also performed neuropsychological test (MMN and Synk) for patients receiving DBS treatment and conservative treatment. Consistently, we found no significant difference in neuropsychological tests between DBS group and conservative group preoperatively, which indicate that the residual consciousness before treatment is similar. In this way, the selection bias was minimized. However, we have carefully studied the existing...
CONCLUSION AND PROSPECTS

DBS was associated with improvements in consciousness in this cohort analysis; therefore, it represents a promising neuromodulation technique to promote the improvement in consciousness in patients with DoC. The DBS-induced improvements in patients with DoC lasted for a long time, and the therapeutic effect was significantly greater for patients with MCS than patients with VS/UWS. For patients with MCS, the six subscales of the CRS-R all exhibited improvement; in contrast, for patients with VS, DBS mainly improved communication and arousal. In conclusion, patients with DoC should be carefully evaluated before selecting DBS as the treatment option. Further closed-loop stimulation strategies may promote recovery along with modern electrophysiological and neuroimaging technologies.

Author affiliations
1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
2Translational Medicine Center, Chinese Institute for Brain Research, Beijing, China
3Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
4Department of Neurosurgery, PLA General Hospital, Beijing, China
5Academician Office, China National Clinical Research Center for Neurological Diseases, Beijing, China

Acknowledgements
The authors thank Xingyue Zhang for reviewing the statistical analysis, which was essential to the successful completion of this study.

Contributors
JH is responsible for the overall content. YY and JH designed the study. YY and QH wrote the manuscript and performed the statistical analysis. XXi, Xiu, YD and XC collected the data. JZ reviewed the manuscript.

Funding
This research was supported by the following funding sources: the National Natural Science Foundation of China (81800919), Beijing Municipal Science and Technology Commission (Z16110000516165 and Z17110000171762) and Beijing Nova Program (Z181100006218050).

Competing interests
None declared.

Patient consent for publication
Consent obtained from parent(s)/guardian(s).

Ethics approval
This study involves human participants and was approved by the Institutional Review Board (IRB) of Beijing Tiantan Hospital, Capital Medical University (KY2017-361-01), and the Ethics Committee of PLA General Hospital (2011–024). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available upon reasonable request.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Guohai He http://orcid.org/0000-0001-6715-298X

REFERENCES